APA (7th ed.) Citation

M, M., M, T., M, S., D, C., R, V., I, T., . . . J, W. (2024). DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO molecular medicine, 16(7), 1603. https://doi.org/10.1038/s44321-024-00088-0

Chicago Style (17th ed.) Citation

M, Momeny, et al. "DUSP6 Inhibition Overcomes Neuregulin/HER3-driven Therapy Tolerance in HER2+ Breast Cancer." EMBO Molecular Medicine 16, no. 7 (2024): 1603. https://doi.org/10.1038/s44321-024-00088-0.

MLA (9th ed.) Citation

M, Momeny, et al. "DUSP6 Inhibition Overcomes Neuregulin/HER3-driven Therapy Tolerance in HER2+ Breast Cancer." EMBO Molecular Medicine, vol. 16, no. 7, 2024, p. 1603, https://doi.org/10.1038/s44321-024-00088-0.